The firm, a specialist provider of perinatal and pediatric pharmacology services, is the 27th company to move into the park joining CRO peers like Biodoxis and Oroxcell.
PupPharma chairman David Chauvier said the firm chose to base itself at Biocitech “because of the high level of services and the very high-quality premises we have been given to expand our activities.”
“Biocitech’s international reputation will also give us greater visibility and credibility for our international expansion.”
Jean-François Boussard, president of Biocitech agreed, adding that: “The company will consolidate the network of innovative CROs installed on the campus and help strengthen their visibility among client companies in France and abroad.”